22 / 25
Page 66
Mater Sci Nanotechnol 2017 | Volume 1 Issue 2
allied
academies
Nanomaterials and Nanochemistry
November 29-30, 2017 | Atlanta, USA
International Conference on
M
etallic drug nano conjugate chemistry is an
interdisciplinary thrust area of cancer biology research;
is currently much more known for its many applications
in drug delivery and also has enormous potential to act
as diagnostic agent. Development of new drug design and
therapeutic strategies that could target cancer cells leaving
normal cells unaffected still continues to be a challenge.
Series of new metallic drug nano conjugate were designed,
synthesized and characterized by, TEM, SEM and various
spectroscopic methods.
In vitro
DNA binding studies of
the compounds investigated by absorption and emission
titrationmethods which revealed that compounds recognizes
the minor groove of DNA in accordance with molecular
docking studies with the DNA. Gel electrophoretic assay
demonstrates the ability of compounds to cleave pBR322
DNA through hydrolytic/oxidative process which was further
validated by T4 religation assay. To understand the metallic
nano drug–protein interaction of which ultimate molecular
target was DNA, the affinity of compounds towards HSA
was also investigated by the spectroscopic and molecular
modeling techniques which showed hydrophobic interaction
in the subdomain IIA of HSA. Furthermore, nano conjugate
showed high inhibitory activity against Topo-Iα suggesting
that new nano conjugate is an efficient DNA cleaving agent.
In vitro
studies on the anticancer activity against the cancer
cell lines revealed that nano conjugates have the capability
to kill the cancer cell. The efficiency of new nano conjugates
is higher than the earlier reported.
e:
tsartaj62@yahoo.comThe progress of nano metallic drug conjugate in cancer chemotherapy
Sartaj Tabassum
King Saud University, Saudi Arabia